Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors

Pharmacological Reviews

Volumn 51, Issue 4, 1999, Pages 691-743

  Drummond, Daryl C ^a   Meyer, Olivier ^a,b,c   Hong, Keelung ^a   Kirpotin, Dmitri B ^a,c   Papahadjopoulos, Demetrios ^d  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b TRANSGENE S A   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; LIPOSOME; METHOTREXATE; NAVELBINE; PACLITAXEL; SPARFOSIC ACID; TOPOTECAN; VINBLASTINE; VINCRISTINE;

AIDS RELATED COMPLEX; ALOPECIA; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CARDIOTOXICITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DYSESTHESIA; GASTROINTESTINAL TOXICITY; HUMAN; KAPOSI SARCOMA; LIPID SOLUBILITY; MUCOSA INFLAMMATION; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; LIPOSOMES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0032758610     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (409)

1. Abra RM and Hunt CA (1981) Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta 666:493-503.
2. Afzelius P, Demant EJF, Hansen GH and Jensen PB (1989) Covalent modification of serum transferrin with phospholipid and incorporation into liposomal membranes. Biochim Biophys Acta 979:231-238.
3. Ahl PL, Bhatia SK, Meers P, Roberts P, Stevens R, Dause R, Perkins WR and Janoff AS (1997) Enhancement of the in vivo circulation lifetime of L-α-distearoylphos-phatidylcholine liposomes: Importance of liposomal aggregation versus complement opsonization. Biochim Biophys Acta 1329:370-382.
4. Ahmad I, Longenecker M, Samuel J and Allen TM (1993) Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 53:1484-1488.
5. Alberts DS and Garcia DJ (1997) Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54 (Suppl 4):30-35.
6. Allen TM (1981) A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. Biochim Biophys Acta 640:385-397.
7. Allen TM (1994) The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv Drug Del Rev 13:285-309.
8. Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect in the future. Drugs 56:747-756.
9. Allen TM, Ahmad I, Lopes de Menezes DE and Moase EH (1995c) Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem Soc Trans 23:1073-1079.
10. Allen TM and Chonn A (1987) Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223:42-46.
11. Allen TM and Cleland LG (1980) Serum-induced leakage of liposome contents. Biochim Biophys Acta 597:418-426.
12. Allen TM and Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim Biophys Acta 1068:133-141.
13. Allen TM, Hansen CB, Kao GY, Ma J, Marjan JMJ, Demenezes DL, Moase EH, Qi W and Stuart D (1997) Antibody-targeted liposomes: Prospects and problems. Adv Drug Del Rev 24:243.
14. Allen TM, Hansen CB and Lopes de Menezes DE (1995a) Pharmacokinetics of long-circulating liposomes. Adv Drug Del Rev 16:267-284.
15. Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
16. Allen TM, Hansen C and Rutledge J (1989) Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981:27-35.
17. Allen TM, Hansen CB and Stuart DD (1998) Targeted sterically stabilized liposomal drug delivery, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 545-565, Elsevier Science BV, New York.
18. Allen TM, Mehra T, Hansen C and Chin YC (1992) Stealth liposomes: An improved sustained release system for 1-β-D-arabinofuranosylcytosine. Cancer Res 52:2431-2439.
19. Allen TM and Moase EH (1996) Therapeutic opportunities for targeted liposomal drug delivery. Adv Drug Del Rev 21:117-133.
20. Allen TM, Murray L, Alving CR and Moe J (1987) Effects of the murine mononuclear phagocyte system of chronic administration of liposomes containing cytotoxic drug or lipid A compared with empty liposomes. Can J Physiol Pharmacol 65:185-190.
21. Allen TM, Murray L, MacKeigan S and Shah M (1984) Chronic liposome administration in mice: Effects on reticuloendothelial function and tissue distribution. J Pharmacol Exp Ther 229:267-275.
22. Allen TM, Newman MS, Woodle MC, Mayhew E and Uster PS (1995b) Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62:199-204.
23. Allen TM and Smuckler EA (1985) Liver pathology accompanying chronic liposome administration in mouse. Res Commun Chem Pathol Pharmacol 50:281-290.
24. Allen TM and Stuart DD (1999) Liposome pharmacokinetics. Classical, sterically-stabilized, cationic liposomes and immunoliposomes, in Liposomes: Rational Design (Janoff AS ed) pp 63-87, Marcel Dekker, Inc, New York.
25. Allen TM, Williamson P and Schlegel RA (1988) Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc Natl Acad Sci USA 85:8067-8071.
26. Allison BA, Pritchard PH, Richter AM and Levy JG (1990) The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 52:501-507.
27. Alving CR and Wassef NM (1992) Complement-dependent phagocytosis of liposomes: Suppression by "stealth" lipids. J Liposome Res 2:383-395.
28. Amantea M, Newman MS, Sullivan TM, Forrest A and Working PK (1999) Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 18:17-26.
29. Amantea MA, Forrest A, Northfelt DW and Mamelok R (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61:301-311.
30. Antony AC (1992) The biological chemistry of folate receptors. Blood 79:2807-2820.
31. Antony AC (1996) Folate receptors. Annu Rev Nutr 16:501-521.
32. Aragnol D and Leserman LD (1986) Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA 83:2699-2703.
33. Averbuch SD, Boldt M, Gaudiano G, Stem JB, Koch TH and Bachur NR (1988) Experimental chemotherapy-induced skin necrosis in swine: Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. J Clin Invest 81:142-148.
34. Averbuch SD, Gaudiano G, Koch TH and Bachur NR (1985) Radical dimer rescue of toxicity and improved therapeutic index of adriamycin in tumor-bearing mice. Cancer Res 45:6200-6204.
35. Averbuch SD, Gaudiano G, Koch TH and Bachur NR (1986) Doxorubicin-induced skin necrosis in the swine model: Protection with a novel radical dimer. J Clin Oncol 4:88-94.
36. Bach D, Miller IR and Sela BA (1982) Calorimetric studies on various gangliosides and ganglioside-lipid interactions. Biochim Biophys Acta 686:233-239.
37. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS and Falk RE (1989) Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23:81-86.
38. Bally MB, Lim H, Cullis PR and Mayer LD (1998) Controlling the drug delivery attributes of lipid-based drug formulations. J Liposome Res 8:299-335.
39. Bally MB, Masin D, Nayar R, Cullis PR and Mayer LD (1994) Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34:137-146.
40. Bally MB, Nayar R, Masin D, Cullis PR and Mayer LD (1990a) Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27:13-19.
41. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR and Mayer LD (1990b) Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023:133-139.
42. Banerjee G, Nandi G, Mahato SB, Pakrashi A and Basu MK (1996) Drug delivery system: Targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother 38:145-150.
43. Barenholz Y (1998) Design of liposome-based drug carriers: From basic research to application as approved drugs, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 545-565, Elsevier Science BV, New York.
44. Barenholz Y, Amselem S, Goren D, Cohen R, Gelvan D, Samuni A, Golden EB and Gabizon A (1993) Stability of liposomal doxorubicin formulations: Problems and prospects. Med Res Rev 13:449-491.
45. Barenholz Y and Cohen R (1995) Rational design of amphiphile-based drug carriers and sterically stabilized carriers. J Liposome Res 5:905-932.
46. Barton PG and Gunstone FD (1975) Hydrocarbon chain packing and molecular motion in phospholipid bilayers formed from unsaturated lecithins: Synthesis and properties of sixteen positional isomers of 1,2-dioctadecenoyl-sn-glycero-3-phosphorylcholine. J Biol Chem 250:4470-4476.
47. Basanez G, Goni FM and Alonso A (1997) Poly(ethylene glyco)-lipid conjugates inhibit phospholipase C-induced lipid hydrolysis, liposome aggregation and fusion through independent mechanisms. FEBS Lett 411:281-286.
48. Batist G, Winer E, Navari R, Rovira D and Azarnia N (1998) Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomized trial of metastatic breast carcinoma (MBC) (Abstract). Proc Am Soc Clin Oncol 17:115.
49. Baxter LT and Jain RK (1990) Transport of fluid and macromolecules in tumors. II. Role of heterogeneous pressure and convection. Microvasc Res 40:246-263.
50. Beaumier PL, Hwang KJ and Slattery JT (1983) Effect of liposome dose on the elimination of small unilamellar sphingomyelin/cholesterol vesicles from the circulation. Res Commun Chem Pathol Pharmacol 39:277-289.
51. Benjamin RS, Wiernik PH and Bachur NR (1974) Adriamycin. Ann Intern Med 81:414-415.
52. Bennett CL, Golub RM, Stinson TJ, Aboulafia DM, von Roenn J, Bogner J, Goebel FD and Stewart S (1998) Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 18:460-465.
53. Berinstein N, Matthay KK, Papahadjopoulos D, Levy R and Sikic BI (1987) Anti-body-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition. Cancer Res 47:5954-5959.
54. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A and Martin FJ (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711-716.
55. Bertelli G, Gozza A, Forno GB, Vidili MG, Silvestro S, Venurini M, Del Mastro L, Garrone O, Rosso R and Dini D (1995) Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: A prospective clinical study. J Clin Oncol 13:2851-2855.
56. Blasberg RG, Kobayashi T, Patiak CS, Shinohara M, Miyoaka M, Rice JM and Shapiro WR (1981) Regional blood flow, capillary premeability, and glucose utilization in two brain tumor models: Preliminary observations and pharmacokinetic implications. Cancer Treat Rep 65 (Suppl 2):3-12.
57. Blume G and Cevc G (1993) Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta 1146:157-168.
58. Boggs JM, Wang HY, Rangaraj G and Tummler B (1989) Interdigitation of phosphatidylcholine and phosphatidylethanolamine mixed with complexes of acidic lipids and polymixin B or polymixin B nonapeptide. Biochim Biophys Acta 985: 199-210.
59. Boman NL, Masin D, Mayer LD, Cullis PR and Bally MB (1994) Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54:2830-2833.
60. Boman NL, Mayer LD and Cullis PR (1993) Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1152:253-258.
61. Brown PM and Silvius JR (1990) Mechanisms of delivery of liposome-encapsulated cytosine arabinoside to CV-1 cells in vitro: Fluorescence-microscopic and cytotoxicity studies. Biochim Biophys Acta 1023:341-351.
62. Buiting AMJ, Zhou F, Bakker JAJ, Rooijen Nv and Huang L (1996) Biodistribution of clodronate and liposomes used in the liposome mediated macrophage "suicide" approach. J Immunol Methods 192:55-62.
63. Burke TG and Gao X (1994) Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci 83:967-969.
64. Burke TG, Mishra AK, Wani M and Wall ME (1993) Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32:5352-5364.
65. Cabanes A, Tzemach D, Goren D, Horowitz AT and Gabizon A (1998) Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 4:499-505.
66. Carpenter CP, Woodside MD, Kinkead ER, King JM and Sullivan LJ (1971) Repsonse of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicol Appl Pharmacol 18:35-40.
67. Carter SK and Livingston RB (1976) Plant products in cancer chemotherapy. Cancer Treat Rep 60:1141-1156.
68. Casper ES, Schwartz GK, Sugarman A, Leung D and Brennan MF (1997) Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 15:2111-2117.
69. Chabner BA and Longo DL (1996) Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott-Raven, Philadelphia.
70. Chang CW, Barber L, Ouyang C, Masin D, Bally MB and Madden TD (1997) Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75:169-177.
71. Chapman DE and Powis G (1993) Tumor cell drug metabolism and drug resistance, in Drug Resistance in Oncology (Teicher B ed) pp 413-459, Marcel Dekker, Inc, New York.
72. Chobanian JV, Tall AR and Brecher PI (1979) Interaction between unilamellar egg yolk lecithin vesicles and human high density lipoprotein. Biochemistry 18:180-187.
73. Chonn A, Semple SC and Cullis P (1992) Association of blood proteins with large unilamellar liposomes in vivo: Relation to circulation lifetimes. J Biol Chem 267:18759-18765.
74. Chonn A, Semple SC and Cullis PR (1995) β2-Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem 270:25845-25849.
75. Chow DD, Essien HE, Padki MM and Hwang KJ (1989) Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther 248:506-513.
76. Chu CJ, Dijkstra J, Lai M-Z, Hong K and Szoka FC (1990) Efficiency of cytoplasmic delivery by pH sensitive liposomes to cells in culture. Pharm Res 7:824-834.
77. Chu C-J and Szoka FC (1992) Antiviral activity and pharmacokinetics of liposome-encapsulated phosphonoformate in Rauscher murine leukemia virus-infected mice. J Liposome Res 2:67-92.
78. Clemons M, Gharif R and Howell A (1998) The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors. Cancer Treat Rev 24:173-184.
79. Clerc S and Barenholz Y (1995) Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta 1240:257-265.
80. Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E and Saville (1998) Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (Stealth) liposomes: Pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin Cancer Res 4:3077-3082.
81. Collins PD, Connolly DT and Williams TJ (1993) Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 109:195-199.
82. Conley BA, Egorin MJ, Whitacre MY, Carter DC and Zuhowski EG (1993) Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol 33:107-112.
83. Coukell AJ and Spencer CM (1997) Polyethylene glycol-liposomal doxorubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 53:520-538.
84. Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R and Petrelli N (1993) Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 63:2796-2802.
85. Crommelin DJ (1984) Influence of lipid composition and ionic strength on the physical stability of liposomes. J Pharm Sci 73:1559-1563.
86. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD and Fenske DB (1997) Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331:187-211.
87. Daemen T, Hofstede G, Kate MTT, Bakker-Woudenberg IAJM and Scherphof G (1995) Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 61:716-721.
88. Daemen T, Regts J, Meesters M, Ten Kate MT, Bakker-Woudenberg IAJM and Scherphof GL (1997) Toxicity of doxorubicin entrapped within long-circulating liposomes. J Control Release 44:1-9.
89. Damen J, Dijkstra J, Regts J and Scherphof G (1980) Effect of lipoprotein-free plasma on the interaction of human plasma high density lipoprotein with egg yolk phosphatidylcholine liposomes. Biochim Biophys Acta 620:90-99.
90. Damen J, Regts J and Scherphof G (1981) Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins: Dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 665:538-545.
91. Debs RJ, Heath TD and Papahadjopoulos D (1987) Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration. Biochim Biophys Acta 901:183-190.
92. Dellian M, Witwer BP, Salehi HA, Yuan F and Jain RK (1996) Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 149:59-71.
93. Devine DV and Marjan JMJ (1997) The role of immunoproteins in the survival of liposomes in the circulation. CRC Crit Rev Ther Drug Carrier Syst 14:105-131.
94. Devine DV, Wong K, Serrano K, Chonn A and Cullis PR (1994) Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim Biophys Acta 1191:43-51.
95. Dijkstra J, van Galen WJM, Hulstaert CE, Kalicharan D, Roerdink FH and Scherphof GL (1984) Interaction of liposomes with Kupffer cells in vitro. Exp Cell Res 150:161-176.
96. Doroshaw JH (1996) Anthracyclines and antracenediones, in Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner BA and Longo DL eds) pp 409-433, Lippincott-Raven Publishers, Philadelphia.
97. Dorr RT (1990) Antidotes to vesicant chemotherapy extravasations. Blood Rev 4:41-60.
98. Eckardt JR, Campbell E, Burris HA, Weiss GR, Rodriguez GI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenberg ML, Ross ME and Von Hoff DD (1994) A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol 17:498-501.
99. Embree L, Gelmon KA, Lohr A, Mayer LD and Coldman AJ (1993) Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J Pharm Sci 82:627-634.
100. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB and Mayer LD (1998) Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41:347-352.
101. Endicott JA and Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171.
102. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S and Stephens R (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57-63.
103. Fan D, Bucana CD, O'Brian CA, Zwelling LA, Seid C and Fidler IJ (1990) Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res 50:3619-3626.
104. Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.
105. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203.
106. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
107. Fonseca GA, Valero V, Buzdar A, Walters R, Willey J, Benjamin R, Ewer M, Mackay B, Gordon D and Hortobagyi G (1995) Decreased cardiac toxicity of TLC D-99 (liposomal doxorubicin) in the treatment of metastatic breast carcinoma (MBC) (Abstract). Proc Am Soc Clin Oncol 14:99.
108. Forssen E and Willis M (1998) Ligand-targeted liposomes. Adv Drug Delivery Rev 29:249-271.
109. Forssen EA, Coulter DM and Proffitt RT (1992) Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52:3255-3261.
110. Forssen EA, Male-Brune R, Adler-Moore JP, Lee MJA, Schmidt PG, Krasieva TB, Shimizu S and Tromberg BJ (1996) Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome®) within tumor tissue. Cancer Res 56:2066-2075.
111. Forssen EA and Ross ME (1994) DaunoXome® treatment of solid tumors: Preclinical and clinical investigations. J Liposome Res 4:481-512.
112. Frankel EN (1980) Lipid oxidation. Prog Lipid Res 19:1-22.
113. Frankel EN (1985) Chemistry of free radical and singlet oxidation of lipids. Prog Lipid Res 23:197-221.
114. Frankel EN (1987a) Biological significance of secondary lipid oxidation products. Free Radic Res Commun 3:213-225.
115. Frankel EN (1987b) Secondary products of lipid oxidation. Chem Phys Lipids 44:73-85.
116. Frézard F (1994) Fluorimetric determination in biological fluids of the release kinetics of liposome-entrapped doxorubicin. J Liposome Res 4:1063-1073.
117. + permeability, active doxorubicin encapsulation and stability in human serum. Biochim Biophys Acta 1194:61-68.
118. 2, and Fab in tumors. Cancer Res 49:5656-5663.
119. Fukumura D, Yuan F, Monsky WL, Chen Y and Jain RK (1997) Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 151:679-688.
120. Gaber MH, Hong K, Huang SK and Papahadjopoulos D (1995) Thermosensitive sterically stabilized liposomes: Formulation and in vitro studies on the mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 12:1407-1416.
121. Gaber MH, Wu NZ, Hong K, Huang SK, Dewhirst MW and Papahadjopoulos D (1996) Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys 36:1177-1187.
122. Gabizon A, Catane R, Uziely B, Kaufman B and Safra T (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987-992.
123. Gabizon A, Chemla M, Tzemach D, Horowitz AT and Goren D (1996) Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 3:391-398.
124. Gabizon A, Chisin R, Amselem S, Druckmann S, Cohen R, Goren D, Fromer I, Peretz T, Sulkes A and Barenholz Y (1991) Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer 64:1125-1132.
125. Gabizon A, Goren D, Fuks Z, Barenholz Y and Dagan A (1983) Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res 43:4730-4735.
126. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A and Siegal T (1997) Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor-bearing animals. Adv Drug Del Rev 24:337-344.
127. Gabizon A and Martin F (1997) Polyethylene glycol-coated (pegylated)liposomal doxorubicin. Drugs 54 (Suppl 4):15-21.
128. Gabizon A, Meshorer A and Barenholz Y (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77:459-469.
129. Gabizon A and Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumors. Proc Natl Acad Sci USA 85:6949-6953.
130. Gabizon A and Papahadjopoulos D (1992) The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1103:94-100.
131. Gabizon A, Peretz T, Sulkes A, Amselem S, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S and Barenholz Y (1989) Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study. Eur J Cancer Clin Oncol 25:1795-1803.
132. Gabizon A, Price DC, Huberty J, Bresalier RS and Papahadjopoulos D (1990) Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res 50:6371-6378.
133. Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin North Am 8:431-450.
134. Gabizon AA (1995) Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv Drug Del Rev 16:285-294.
135. Gabizon AA (1998) Clinical trials of liposomes as carriers of chemotherapeutic agents: synopsis and perspective, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 625-634, Elsevier Science BV, New York.
136. Gabizon AA, Barenholz Y and Bialer M (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res 10:703-708.
137. Gamon BL, Virden JW and Berg JC (1989) The aggregation kinetics of an electrically stabilized dipalmitoylphosphatidylcholine vesicle system. J Colloid Interface Sci 132:125-138.
138. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P and Mayer LD (1999) Phase I study of liposomal vincristine. J Clin Oncol 17:697-705.
139. Gigli M, Doglia SM, Millot JM, Valentini L and Manfait M (1988) Quantitative study of doxorubicin in living cell nuclei by microspectrofluorimetry. Biochim Biophys Acta 950:13-20.
140. Gill P, Rarick M, Bernstein-Singer M, Harb M, Espina BM, Shaw V and Levine A (1990) Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 13:315-319.
141. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A and Esplin JA (1995) Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 13:996-1003.
142. Gill PS, Miles SA, Mitsuyasu RT, Montgomery T, McCarthy S, Espina BM, Feldstein M and Levine AM (1994) Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi's sarcoma. AIDS 8:1695-1699.
143. Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, Bernstein-Singer M, Akil B, Espina BM, Krailo M and Levine A (1991) Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am J Med 90:427-433.
144. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, Vonroenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC and Ross ME (1996) Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14:2353-2364.
145. Girard PM, Bouchaud O, Goetschel A, Mukwaya G, Eestermans G and Ross M (1996) Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 10:753-757.
146. Goodwin GC, Hammond K, Lyle IG and Jones MN (1982) Lectin-mediated agglutination of liposomes containing glycophorin: Effects of acyl chain length. Biochim Biophys Acta 689:80-88.
147. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR and VonRoenn J (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173.
148. Goren D, Horowitz AT, Zalipeky S, Woodle MC, Yarden Y and Gabizon A (1996) Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies. Br J Cancer 74:1749-1756.
149. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
150. Gregoriadis G (1976) The carrier potential of liposomes in biology and medicine. N Engl J Med 295:704-710.
151. Gregoriadis G and Davis C (1979) Stability of liposome in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochem Biophys Res Commun 89:1287-1293.
152. Gregoriadis G and Senior J (1980) The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 119:43-46.
153. Haran G, Cohen R, Bar LK and Barenholz Y (1993) Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphatic weak bases. Biochim Biophys Acta 1151:201-215.
154. Harashima H, Sakata K and Kiwada H (1993) Distinction between depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes. Pharm Res 10:606-610.
155. Harasym TO, Cullis PR and Bally MB (1997) Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/ cholesterol liposomes. Cancer Chemother Pharmacol 40:309-317.
156. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ and Cullis PR (1993) Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta 1149:329-338.
157. Harris L, Winer E, Batist G, Rovira D, Navaria R and Lee L (1998) Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC) (Abstract). Proc Am Soc Clin Oncol 17:124.
158. Harrison M, Tomlinson D and Stewart S (1995) Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920.
159. Harvie P, Désormeaux A, Bergeron M-C, Tremblay M, Beauchamp D, Poulin L and Bergeron MG (1996) Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2′,3′-dideoxyinosine. Antimicrob Agents Chemother 40:225-229.
160. Heath TD and Brown CS (1989) Liposome dependent delivery of N-(phosphonyl)-L-aspartic acid to cells in vitro. J Liposome Res 1:303-317.
161. Heath TD, Montgomery JA, Piper JR and Papahadjopoulos D (1983) Antibody-targeted liposomes: Increase in specific toxicity of methotrexate-γ-aspartate. Proc Natl Acad Sci USA 80:1377-1381.
162. Hengge UR, Brockmeyer NH, Rabhofer R and Goos M (1993) Hepatic failure with liposomal doxorubicin. Lancet 341:383-384.
163. Henry D (1997) Haematological toxicities associated with dose-intensive chemotherapy: The role for and use of recombinant growth factors. Ann Oncol 8:S7-S10.
164. Herman EH, Rahman A, Ferrans VJ, Vick JA and Schein PS (1983) Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 43:5427-5432.
165. Heuff G, Oldenburg HSA, Boutkan H, Visser JJ, Beelen RHJ, Van Rooijen N, Dijkstra CD and Meyer S (1993) Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. Cancer Immunol Immunother 37:125-130.
166. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP and Jain RK (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607-4612.
167. Hoff PM, Valero V, Ibrahim N, Willey J and Hortobagyi GN (1998) Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 82: 965-969.
168. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD and Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (Wash DC) 284:1994-1998.
169. Holland JW, Cullis PR and Madden TD (1996a) Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer forming lipids. Biochemistry 35:2610-2617.
170. Holland JW, Hui C, Cullis PK and Madden TD (1996b) Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry 35:2618-2624.
171. Holmgren L, O'Reilly MS and Folkman J (1995) Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153.
172. Horowitz AR, Barenholz Y and Gabizon AA (1992) In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. Biochim Biophys Acta 1109:203-209.
173. Hortobagyi GN, Frye D, Buzdar AU, Ewer MS, Fraschini G, Hug V, Ames F, Montague E, Carrasco CH, Mackay B and Benjamin RS (1989) Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45.
174. Huang A, Kennel SJ and Huang L (1983) Interactions of immunoliposomes with target cells. J Biol Chem 258:14034-14040.
175. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D and Friend DS (1993) Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV Tat gene. Am J Pathol 143:10-14.
176. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ and Papahadjopoulos D (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774-6781.
177. Huang SK, Stauffer PR, Hong K, Guo JWH, Phillips TL, Huang A and Papahadjopoulos D (1994) Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 54:2186-2191.
178. Hwang KJ (1987) Liposome Pharmacokinetics, in Liposomes: From Biophysics to Therapeutics (Ostro MJ ed) pp 109-156, Marcel Dekker, Inc, New York.
179. Jain R (1987) Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-3051.
180. Jain RK (1989) Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 81:570-576.
181. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50 (3 Suppl):814s-819s.
182. Jain RK (1996) Delivery of molecular medicine to solid tumors. Science (Wash DC) 271:1079-1080.
183. Jain RK and Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48:7022-7032.
184. Jett M, Chudzik J, Alving CR and Stanacev NZ (1985) Metabolic fate of liposomal phosphatidylinositol in murine tumor cells: Implications for the mechanism of tumor cell cytotoxicity. Cancer Res 48:4810-4815.
185. Jones CB, Clements MK, Wasi S and Daoud SS (1997) Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells. Cancer Chemother Pharmacol 40:475-483.
186. Jones M and Hudson MJH (1993) The targeting of immunoliposomes to tumour cells (A431) and the effects of encapsulated methotrexate. Biochim Biophys Acta 1152: 231-242.
187. Kamen BA, Smith AK and Anderson RGW (1991) The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. J Clin Invest 87:1442-1449.
188. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PD and Pavelic ZP (1993) Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 7:17-26.
189. Kanter PM, Klaich GM, Bullard GA, King JM, Bally M and Mayer LD (1994) Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats, and dogs. Anti-cancer Drugs 5:579-590.
190. Kirpotin D, Hong K, Mullah N, Papahadjopoulos D and Zalipsky S (1996) Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphati-dylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett 388:115-118.
191. Kirpotin D, Park JW, Hong K, Zalipsky S, Li W-L, Carter P, Benz CC and Papahadjopoulos D (1997b) Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75.
192. Kirpotin DB, Park JW, Demetzos K, Meyer O, Colbern G, Uster P and Hong K (1999a) Stealth® liposomal vinorelbine: Synthesis, stability and antitumor activity against human breast and lung cancer xenografts (Abstract). Proc Am Assoc Cancer Res 40:417.
193. Kirpotin DB, Park JW, Hong K, Shao Y, Colbern G, Zheng W-W, Meyer O, Benz CC and Papahadjopoulos D (1998) Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 325-345, Elsevier Science BV, New York.
194. Kirpotin DB, Park JW, Hong K, Shao Y, Shalaby R, Colbern G, Benz CC and Papahadjopoulos D (1997a) Targeting of liposomes to solid tumors: The case of sterically stabilized anti-HER2 immunoliposomes. J Liposome Res 7:391-417.
195. Kirpotin DB, Stauffer PS, Diedrich CJ, Hong K, Shao Y, Park JW, Benz CC and Papahadjopoulos D (1999b) Optimization of liposome uptake by human breast cancer xenografts in response to hyperthermia. 18th Annual Meeting of North American Hyperthermia Society; 1999 April 8-10; Philadelphia.
196. Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP and Huang L (1991) Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposomes binding to target. Biochim Biophys Acta 1062:142-148.
197. Klibanov AL, Maruyama K, Torchilin VP and Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268: 235-237.
198. Krill SL, Knutson K and Higuchi WI (1992) Ethanol effects on the stratum corneum lipid phase behavior. Biochim Biophys Acta 1112:273-280.
199. Krishna R and Mayer LD (1997) Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 57:5246-5253.
200. Lasic D and Martin F (1995) Stealth Liposomes, CRC Press, Boca Raton, FL.
201. Lasic DD (1993) Liposomes: From Physics to Applications, Elsevier, New York.
202. Lasic DD, Ceh B, Stuart MCA, Guo L, Frederik PM and Barenholz Y (1995) Transmembrane gradient driven phase transitions within vesicles: Lessons for drug delivery. Biochim Biophys Acta 1239:145-156.
203. Lasic DD, Frederick PM, Stuart MCA, Barenholz Y and McIntosh TJ 1992a) Gelation of liposome interior: A novel method for drug encapsulation. FEBS Lett 312:255-258.
204. Lasic DD, Martin FJ, Gabizon A, Huang SK and Papahadjopoulos D (1991) Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070:187-192.
205. Lasic DD and Needham D (1995) The "stealth" liposome: A prototypical biomaterial. Chem Rev 95:2601-2628.
206. Lasic DD and Papahadjopoulos D (1996) Liposomes and biopolymers in drug and gene delivery. Curr Opin Solid State Mater Sci 1:392-400.
207. Lasic DD, Woodle MC and Papahadjopoulos D (1992b) On the molecular mechanism of steric stabilization of liposomes in biological fluids. J Liposome Res 2:335-353.
208. Lee RJ and Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-3204.
209. Lee RJ and Low PS (1995) Folated-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134-144.
210. Legha SS, Hortobagyi GN and Benjamin RS (1987) Anthracyclines, in Cancer Chemotherapy by Infusion (Lokich JJ ed) pp 130-144, Precept Press, Inc, Chicago.
211. Levin VA, Patlak CS and Landahl HD (1980) Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 8:257-275.
212. Levy MH and Wheelock EF (1974) The role of macrophages in defense against neoplastic disease. Adv Cancer Res 20:131-163.
213. Lieschke GJ, Foote M and Morstyn G (1997) Hematopoietic growth factors in cancer chemotherapy. Cancer Chemother Biol Response Modif 17:363-389.
214. Lim HJ, Masin D, Madden TD and Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. JPharmacol Exp Ther 281:566-573.
215. Litzinger DC, Buiting AMJ, van Rooijen N and Huang L (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1190:99-107.
216. Litzinger DC and Huang L (1992) Phosphatidylethanolamine liposomes: Drug delivery, gene transfer, and immunodiagnostic applications. Biochim Biophys Acta 1113:201-227.
217. Liu D and Huang L (1989) Role of cholesterol in the stability of the pH-sensitive, large unilamellar liposomes prepared by the detergent dialysis method. Biochim Biophys Acta 981:254-260.
218. Liu D and Huang L (1990) pH-sensitive, plasma-stable liposomes with relatively prolonged residence in circulation. Biochim Biophys Acta 1022:348-354.
219. 1-containing liposomes. Biochim Biaphys Acta 1104:95-101.
220. Lokich JJ and Moore C (1984) Chemotherapy-associated palmar-plantar erythrodys-esthesia syndrome. Ann Intern Med 101:798-800.
221. Lopes de Menezes DE, Pilarski LM and Allen TM (1998) In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 58:3320-3330.
222. Lum H and Malik AB (1994) Regulation of vascular endothelial barrier function. Am J Physiol 267:L223-L241.
223. Lundberg B, Hong K and Papahadjopoulos D (1993) Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim Biophys Acta 1149:305-312.
224. Machy P, Barbet J and Leserman LD (1982) Differential endocytosis of T and B lymphocyte surface molecules evaluated with antibody-bearing fluorescent liposomes containing methotrexate. Proc Natl Acad Sci USA 79:4148-4152.
225. Madden TD, Harrigan PR, Tai LCL, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CPS, Reinish LW and Cullis PR (1990) The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: A survey. Chem Phys Lipids 53:37-46.
226. Maeda H (1991) SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Del Rev 6:181-202.
227. Maeda H and Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. CRC Crit Rev Ther Drug Carrier Syst 6:193-210.
228. Martin FJ (1998) Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin), in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 635-688, Elsevier Science BV, New York.
229. Maruyama K, Holmberg E, Kennel SJ, Klibanov A, Torchilin VP and Huang L (1990a) Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 79:978-984.
230. Maruyama K, Kennel SJ and Huang L (1990b) Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proc Natl Acad Sci USA 87:5744-5748.
231. Matsumura Y and Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387-6392.
232. Matthay KK, Abai AM, Cobb S, Hong K, Papahadjopoulos D and Straubinger RM (1989) Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia celle. Cancer Res 49:4879-4886.
233. Matthay KK, Heath TD, Badger CC, Bernstein ID and Papahadjopoulos D (1986) Antibody-directed liposomes: Comparison of various ligands for association, endocytosis, and drug delivery. Cancer Res 46:4904-4910.
234. Mayer LD, Bally MB, Cullis PR, Wilson SL and Emerman JT (1990a) Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53:183-190.
235. Mayer LD, Bally MB, Hope MJ and Cullis PR (1985) Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816:294-302.
236. Mayer LD, Bally MB, Loughrey H, Masin D and Cullis PR (1990b) Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50:575-579.
237. Mayer LD, Cullis PR and Bally MB (1998) Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes, in Medical Applications of Liposomes (Papahadjopoulos D and Lasic D, eds) pp 231-257, Elsevier Science BV, New York.
238. Mayer LD, Dougherty G, Harasym TO and Bally MB (1997) The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280:1406-1414.
239. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR and Bally MB (1993) Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33:17-24.
240. Mayer LD, Tai LCL, Bally MB, Mitilenes GN, Ginsberg RS and Cullis PR (1990c) Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025:143-151.
241. Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR and Bally MB (1989) Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922-5930.
242. Mayhew E, Rustum YM, Szoka F and Papahadjopoulos D (1979) Role of cholesterol in enhancing the antitumor activity of cystosine arabinoside entrapped in liposomes. Cancer Treat Rep 63:1923-1928.
243. Mayhew EG, Goldrosen MH, Vaage J and Rustum YM (1987) Effects of liposome-entrapped doxorubicin in liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst 78:707-713.
244. Mayhew EG, Lasic D, Babbar S and Martin FJ (1992) Pharmacokinetics and anti-tumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer 51:302-309.
245. Meyer O, Kirpotin D, Hong K, Sternberg B, Park JW, Woodle MC and Papahadjopoulos D (1998a) Cationic liposomes coated with polyethylene glycol as carriers of oligonucleotides. J Biol Chem 273:15621-15627.
246. Meyer O, Papahadjopoulos D and Leroux J-C (1998b) Copolymers of N-isopropylacrylamide can trigger pH sensitivity to stable liposomes. FEBS Lett 421:61-64.
247. Mickisch GH, Rahman A, Pastan I and Gottesman MM (1992) Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 84:804-805.
248. Mitsuyasu R, yon Roenn J, Krown S, Kaplan L and Testa M (1997) Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of advanced AIDS associated Kaposi's sarcoma (AIDS-KS): AIDS Clinical Trial Group (ACTG) protocol 286 (Abstract). Proc Am Soc Clin Oncol 16:55.
249. Mori A, Kennel SJ and Huang L (1993) Immunotargeting of liposome containing lipophilic antitumor prodrugs. Pharm Res 10:507-514.
250. Mori A, Kennel SJ, Waalkes MvB, Scherphof GL and Huang L (1995) Characterization of organ-specific immunoliposomes for delivery of 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine in a mouse lung-metastasis model. Cancer Chemother Pharmacol 35:447-456.
251. Mori A, Klibanov AL, Torchilin VP and Huang L (1991) Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 284:263-266.
252. Mori A, Wu S-P, Han I, Khokhar AR, Perez-Soler R and Huang L (1996) In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol 37:435-444.
253. Muggia FM (1997) Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 54:22-29.
254. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A and Greco FA (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993.
255. Mui BL-S, Cullis PR, Evans EA and Madden TD (1993) Osmotic properties of large unilamellar vesicles prepared by extrusion. Biophys J 64:443-453.
256. Mui BL-S, Cullis PR, Pritchard PH and Madden TD (1994) Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. J Biol Chem 269:7364-7370.
257. Needham D, Hristova K, McIntosh TJ, Dewhirst M and Lasic DD (1992a) Polymergrafted liposomes: Physical basis for the "stealth" property. J Liposome Res 2:411-430.
258. Needham D, McIntosh TJ and Lasic DD (1992b) Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1108:40-48.
259. Needham D, Zhelev DV and McIntosh TJ (1999) Surface chemistry of the sterically stabilized PEG-liposome, in Liposomes: Rational Design (Janoff AS ed) pp 13-62, Marcel Dekker, Inc, New York.
260. Nemunaitis J (1997) A comparative review of colony-stimulating factors. Drugs 54:709-729.
261. Newman MS, Colbern GT, Working PK, Engbers C and Amantea M (1999) Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cis-platin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7.
262. Nichols JW and Deamer DW (1976) Catecholamine uptake and concentration by liposomes maintaining pH gradients. Biochim Biophys Acta 455:269-271.
263. Northfelt DW (1994) AIDS-related Kaposi's sarcoma: Still a problem, still an opportunity. J Clin Invest 12:1109-1110.
264. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C and Mamaelok RD (1997) Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659.
265. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Mond CD, Mamelok RD and Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451.
266. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA and Kaplan LD (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 38:55-63.
267. Oja CD, Semple SC, Chonn A and Cullis PR (1996) Influence of dose on liposome clearance: Critical role of blood proteins. Biochim Biophys Acta 1281:31-37.
268. Olson F, Hunt CA, Szoka FC, Vail WJ and Papahadjopoulos D (1979) Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 557:9-23.
269. Olson F, Mayhew E, Maslow D, Rustum Y and Szoka F (1982) Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer Clin Oncol 18:167-176.
270. Olver IN, Aisner J, Hament A, Buchanan L, Bishop JF and Kaplan RS (1988) A prospective study of topical dimethyl sulfoxide for treating anthracycline. J Clin Oncol 6:1732-1735.
271. Oudard S, Thierry A, Jorgensen TJ and Rahman A (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28:259-265.
272. Oussoren C, Eling WMC, Crommelin DJA, Storm G and Zuidema J (1998) The influence of the route of administration and liposome composition on the potential of liposomes to protect tissue against local toxicity of two antitumor drugs. Biochim Biophys Acta 1369:159-172.
273. Owellen RJ, Hartke CA, Dickerson RM and Hains FO (1976) Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36: 1499-1502.
274. Pak CC, Ali S, Janoff AS and Meers P (1997) Triggerable liposome fusion by enzymatic cleavage of a novel peptide-lipid conjugate. Biochim Biophys Acta 1372: 13-27.
275. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C and Martin FJ (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
276. Papahadjopoulos D, Cowden M and Kimelberg H (1973a) Role of cholesterol in membranes: Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim Biophys Acta 330:8-26.
277. Papahadjopoulos D and Gabizon AA (1995) Sterically stabilized (Stealth®) liposomes: Pharmacological properties and drug carrying potential in cancer, in Liposomes as Tools in Basic Research and Industry (Philippot JR and Schuber F eds) pp 177-188, CRC Press, Boca Raton, FL.
278. Papahadjopoulos D, Jacobson K, Nir S and Isac T (1973b) Phase transitions in phospholipid vesicles: Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochim Biophys Acta 311: 330-348.
279. Papahadjopoulos D, Kirpotin DB, Park JW, Hong K, Shao Y, Shalaby R, Colbern G and Benz CC (1999) Targeting of drugs to solid tumors using anti-HER2 immunoliposomes. J Liposome Res 8:425-442.
280. Papahadjopoulos D, Nir S and Oki S (1972) Permeability properties of phospholipid membranes: Effect of cholesterol and temperature. Biochim Biophys Acta 266: 561-583.
281. Parente RA, Nadasdi L, Subbarao NK and Szoka FC (1990) Association of a pH-sensitive peptide with membrane vesicles: Role of amino acid sequence. Biochemistry 29:8713-8719.
282. Parente RA, Nir S and Szoka FC Jr (1988) pH-dependent fusion of phosphatidylcholine small vesicles: Induction by a synthetic amphipathic peptide. J Biol Chem 263:4724-4730.
283. HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 92:1327-1331.
284. Park JW, Hong K, Kirpotin DB, Papahadjopoulos D and Benz CC (1997) Immunoliposomes for cancer treatment. Adv Pharmacol 40:399-435.
285. Park JW, Kirpotin D, Hong K, Colbern G, Shalaby R, Shao Y, Meyer O, Nielson U, Marks J, Benz CC and Papahadjopoulos D (1998a) Anti-HER2 immunoliposomes for targeted drug delivery. Med Chem Res 8:383-391.
286. Park JW, Kirpotin D, Hong K, Zheng W, Shao Y, Meyer O, Benz CC and Papahadjopoulos D (1998b) Sterically stabilized immunoliposomes: Formulations for delivery of drugs and genes to tumor cells in vivo, in Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems (Gregoriadis G and McCormack B eds) pp 41-47, Plenum Press, New York.
287. Park YS, Maruyama K and Huang L (1992) Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. Biochim Biophys Acta 1108: 257-260.
288. Parr MJ, Ansell SM, Choi LS and Cullis PR (1994) Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta 1195:21-30.
289. Parr MJ, Bally MB and Cullis PR (1993) The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168:249-252.
290. Parr MJ, Masin D, Cullis PR and Bally MB (1997) Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinoma: The lack of beneficial effects of coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280:1319-1327.
291. Pastan I and Gottesman MM (1991) Multidrug resistance. Annu Rev Med 42:277-286.
292. Patel HM (1992) Serum opsonins and liposomes: Their interaction and opsonoph-agocytosis. CRC Crit Rev Ther Drug Carrier Syst 9:39-90.
293. Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D, Raber MN and Khokhar AR (1990) Phase I clinical and pharmacologic study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocylcohex-aneplatinum (II). Cancer Res 50:4252-4259.
294. Perrin VL (1995) Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 10:334-52.
295. Petros WP and Peters WP (1996) Colony-stimulating factors, in Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner BA and Longo DL eds) pp 639-654, Lippincott-Raven Publishers, Philadelphia.
296. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter G, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M and Rilke F (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417-1423.
297. Pinnaduwage P and Huang L (1988) β-Galactosidase-induced destabilization of liposome composed of phosphatidylethanolamine and ganglioside GM1. Biochim Biophys Acta 939:375-382.
298. Plageman PGW, Marz R and Wohlhueter RM (1978) Transport and metabolism of deoxycytidine and 1-β-D-arabinofuranosyl-cytosine into cultured Novikoff rap hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res 38:978-989.
299. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J and Presant J (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341:1242-1243.
300. Qian Q, Jutila MA, Van Rooijen N and Cutler JE (1994) Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol 152:5000-5008.
301. Raghavan M and Bjorkman PJ (1996) Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 12:181-220.
302. Rahman A, Husain SR, Siddiqui J, Verma M, Agresti M, Center M, Safa AR and Glazer RI (1992) Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst 84:1909-1915.
303. Rahman A, Treat J, Roh JK, Potkul LA, Alvord WG, Forst D and Woolley PV (1990) A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093-1100.
304. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D and Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial. J Clin Oncol 15:3185-3191.
305. Reddi E (1997) Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumors. J Photochem Photobiol B 37:189-195.
306. Richardson VJ and Ryman BE (1982) Effect of liposomally trapped antitumour drugs on a drug-resistant mouse lymphoma in vivo. Br J Cancer 45:552-558.
307. Ringel I and Horwitz SB (1987) Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium. J Pharmacol Exp Ther 242:692-693.
308. Roberts WG and Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced endothelial growth factor. J Cell Sci 108:2369-2379.
309. Roh MS, Kahky MP, Oyedeji C, Klostergaard J, Wang L, Curley SA and Lotzová E (1992) Murine Kupffer cells and hepatic natural killer cells regulate tumor growth in a quantitative model of colorectal liver metastases. Clin Exp Metastasis 10:317-327.
310. Rosenecker J, Zhang W, Hong K, Lausier J, Geppetti P, Yoshihara S, Papahadjopoulos D and Nadel JA (1996) Increased liposome extravasation in selected tissues: Effect of substance P. Proc Natl Acad Sci USA 93:7236-7241.
311. Ross JF, Chaudhuri PK and Ratnam M (1994) Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer 73:2432-2443.
312. Rowinsky EK and Donehower RC (1996) Antimicrotubule agents, in Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner BA and Longo DL eds) pp 263-296, Lippincott-Raven Publishers, Philadelphia.
313. Sanchez-Migallon MP and Aranda FJ (1996) Interaction between α-tocopherol and heteroacid phosphatidylcholines with different amounts of unsaturation. Biochim Biophys Acta 1279:251-258.
314. Sankaram MB and Thompson TE (1990) Interaction of cholesterol with various glycerophospholipids and sphingomyelin. Biochemistry 29:10670-10675.
315. Scherer PG and Seelig J (1989) Electric charge effects on phospholipid headgroups. Phosphatidylcholine in mixtures with cationic and anionic amphiphiles. Biochemistry 28:7720-7728.
316. Scherphof G, Roerdink F, Waite M and Parks J (1978) Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 542:296-307.
317. Scherphof GL, Morselt H and Allen TM (1994) Intrahepatic distribution of long-circulating liposomes containing poly(ethylene glycol) distearoylphosphatidyleth-anolamine. J Liposome Res 4:213-228.
318. Schmidt CF, Barenholz Y and Thompson TE (1977) A nuclear magnetic resonance study of sphingomyelin in bilayer systems. Biochemistry 16:2649-2656.
319. Schmidt PG, Adler-Moore JP, Forssen EA and Proffit RT (1998) Unilamellar liposomes for anticancer and antifungal therapy, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 703-731, Elsevier Science BV, New York.
320. Semple SC and Chonn A (1996) Liposome-blood protein interactions in relation to liposome clearance. J Liposome Res 6:33-60.
321. Semple SC, Chonn A and Cullis PR (1996) Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry 35:2521-2525.
322. Senior J, Crawley JCW and Gregoriadis G (1985) Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim Biophys Acta 839:1-8.
323. Senior J, Delgado C, Fisher D, Tilcock C and Gregoriadis G (1991) Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles. Biochim Biophys Acta 1062:77-82.
324. Senior J and Gregoriadis G (1982) Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of the phospholipid and cholesterol components. Life Sci 30:2123-2136.
325. Senior JH (1987) Fate and behaviour of liposomes in vivo: A review of controlling factors. CRC Crit Rev Ther Drug Carrier Syst 3:123-193.
326. Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. CRC Crit Rev Ther Drug Carrier Syst 9:135-187.
327. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C and Harmon P (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71:103-107.
328. Sharma A, Sharma US and Straubinger RM (1996) Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia. Cancer Lett 107:265-272.
329. Sharma A, Straubinger RM, Ojima I and Bernacki RJ (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 84:1400-1404.
330. Siegal T, Horowitz A and Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. J Neurosurg 83:1029-1037.
331. Silberstein SD (1997) The pharmacology of ergotamine and dihydroergotamine. Headache 37 (Suppl 1):S15-S25.
332. Simpson JK, Miller RF and Spittle MF (1993) Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma. Clin Oncol 5:372-374.
333. Singh M, Ghose T, Faulkner G, Kralovec J and Mezei M (1989) Targeting of methotrexate-containing liposomes with a monoclonal antibody against human renal cancer. Cancer Res 49:3976-3984.
334. Smaby JM, Momsen M, Kulkarni VS and Brown RE (1996) Cholesterol-induced interfacial area condensations of galactosylceramides and sphingomyelins with identical acyl chains. Biochemistry 35:5696-5704.
335. Spanjer HH and Scherphof GL (1983) Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo. Biochim Biophys Acta 734:40-47.
336. Speth PAJ, van Hoesel QGCM and Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15-31.
337. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J and Dezube BJ (1998) Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 16:683-691.
338. Storm G, Oussoren C, Peeters PAM and Barenholz Y (1993) Tolerability of liposomes in vivo, in Liposome Technology (Gregoriadis G ed) pp 345-383, CRC Press, Inc, Boca Raton, FL.
339. Storm G, Steerenberg PA, Emmen F, Waalkes MvB and Crommelin DJA (1988) Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 965:136-145.
340. Storm G, ten Kate MT, Working PK and Bakker-Woudenberg IA (1998) Doxorubicin entrapped in sterically stabilized liposomes: Effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res 4:111-115.
341. Straubinger RM, Düzgünes N and Papahadjopoulos D (1985) pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett 179: 148-154.
342. Straubinger RM, Hong K, Friend DS and Papahadjopoulos D (1983) Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a Low pH compartment after internalization in coated vesicles. Cell 32:1069-1079.
343. Straubinger RM, Lopez NG, Debs RJ, Hong K and Papahadjopoulos D (1988) Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res 46:5237-5245.
344. Subramanian D and Muller MT (1995) Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol Res 7:461-469.
345. Surewicz WK and Epand RM (1986) Phospholipid structure determines the effects of peptides on membranes: Differential scanning calorimetry studies with pentagastrin-related peptides. Biochim Biophys Acta 856:290-300.
346. Swenson CE, Freitag J and Janoff AS (1998) The Liposome Company: Lipid-based pharmaceuticals in clinical development, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 689-702, Elsevier Science BV, New York.
347. Szoka F, Olson F, Heath T, Vail W, Mayhew E and Papahadjopoulos D (1980) Preparation of unilamellar liposomes of intermediate size (0.1-0.2 μm) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 601:559-571.
348. Szoka F and Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75:4194-4198.
349. Szoka FC (1998) Commentary: Rantosomes and ravosomes. J Liposome Res 8:vii-ix.
350. Takanashi S and Bachur NR (1976) Adriamycin metabolism in man: Evidence from urinary metabolites. Drug Metab Dispos 4:79-87.
351. Thierry AR, Jorgensen TJ, Forst D, Belli JA, Dritschilo A and Rahman A (1989) Multidrug resistance in Chinese hamster cells: Effect of liposome encapsulated doxorubicin. Cancer Commun 1:311-316.
352. Torchilin V, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P and Veronese B (1995) The synthetic amphiphilic polymers for steric protection of liposome in vivo. J Pharm Sci 84:1049-1053.
353. Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV and Rahman A (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. J Natl Cancer Inst 82:1706-1710.
354. Trubetskaya OV, Trubetskoy VS, Domogatsky SP, Rudin AV, Popov NV, Danilov SM, Nikolayeva MN, Klibanov AL and Torchilin VP (1988) Monoclonal antibody to human endothelial cell surface internalization and liposome delivery in cell culture. FEBS Lett 228:131-134.
355. Unezaki S, Mauryama K, Ishida O, Suginaka A, Jun-ichi H and Iwatsuru M (1995) Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol). Int J Pharm 126:41-48.
356. Uthayakumar S, Bower M, Money-Kyrle J, Muyshondt C, Youle M, Hannon F, Phillips R, Gazzard BG and Boag F (1996) Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 10: 515-519.
357. Utkhede DR and Tilcock CP (1998) Effect of lipid dose on the biodistribution and blood pool clearance kinetics of PEG-modified technetium-labeled lipid vesicles. J Liposome Res 8:381-390.
358. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM and Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785.
359. Vaage J, Barberá-Guillem E, Abra R, Huang A and Working P (1994a) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostrate carcinoma xenografts. Cancer 73:1478-1484.
360. Vaage J, Donovan D, Colbern G, Uster P and Working P (1999) Tumor uptake and therapeutic effects of drugs encapsulated in long-circulating pegylated liposomes (Abstract). Proc Am Assoc Cancer Res 40:418.
361. Vaage J, Donovan D, Loftus T, Abra R, Working P and Huang A (1994b) Chemoprevention and therapy of mouse mammary carcinomas with doxorubicin encapsulated in sterically stabilized liposomes. Cancer 73:2366-2371.
362. Vaage J, Donovan D, Mayhew E, Abra R and Huang A (1993a) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72:3671-3675.
363. Vaage J, Donovan D, Mayhew E, Uster P and Woodle MC (1993b) Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer 54:959-964.
364. Vaage J, Donovan D, Uster P and Working P (1997) Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. Br J Cancer 75:482-486.
365. Vaage J, Donovan D, Working P and Uster P (1998) Cellular distribution of DOXIL® within selected tissues, assessed by confocal laser scanning microscopy, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 275-282, Elsevier Science BV, New York.
366. Vaage J, Mayhew E, Lasic D and Martin F(1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 51:942-948.
367. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ and Obradovich JE (1998) Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (stealth) liposomes: A randomized, double blind clinical trial using a canine model. Clin Cancer Res 4:1567-1571.
368. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW and Hortobagyi GN (1999) Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 17:1425-1434.
369. van Bree C, Krooshoop JJ, Rietbroek RC, Kipp JB and Bakker PJ (1996) Hyperthermia enhances tumor uptake and antitumor efficacy of thermostable liposomal daunorubicin in a rat solid tumor. Cancer Res 56:563-568.
370. Vincent JS, Revak SD, Cochrane CG and Levin IW (1991) Raman spectroscopic studies of model human pulmonary surfactant systems: Phospholipid interactions with peptide paradigms for the surfactant protein SP-B. Biochemistry 30:8395-8401.
371. Vingerhoeds MH, Steerenberg PA, Hendriks JJGW, Dekker LC, van Hoesel QGCM, Crommelin DJA and Storm G (1996) Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br J Cancer 74:1023-1029.
372. Vogelzang NJ and Ratain MJ (1985) Cancer chemotherapy and skin changes. Ann Intern Med 103:303-304.
373. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M and Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717.
374. Vose JM and Armitage JO (1995) Clinical applications of hematopoietic growth factors. J Clin Oncol 13:1023-1035.
375. Vukelja SJ, Baker WJ, Bums HA, Keeling JH and Von Hoff D (1993) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 85:1432-1433.
376. Vukelja SJ, Lombardo FA, James WD and Weiss RB (1989) Pyroxidine for palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 111:688-689.
377. Wassef NM, Matyas GR and Alving CR (1991) Complement-dependent phagocytosis of liposomes by macrophages: Suppressive effects of "stealth" lipids. Biochem Biophys Res Commun 176:866-874.
378. Webb MS, Harasym TO, Masin D, Bally MB and Mayer LD (1995) Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72:896-904.
379. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR and Mayer LD (1998) Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372:272-282.
380. Weinstein JN (1984) Liposomes as drug carriers in cancer therapy. Cancer Treat Rep 68:127-135.
381. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM and Keenan AM (1987) The pharmacology of monoclonal antibodies. Ann NY Acad Sci 507:199-210.
382. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V and Zurawski VR (1992a) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401.
383. Weitman SD, Weiberg AG, Coney LR, Zurawski VR, Jennings DS and Kamen BA (1992b) Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Res 52:6708-6711.
384. Welling PG (1986) Pharmacokinetics: Processes and Mathematics, American Chemical Society, Washington, DC.
385. Westerhof GR, Jansen G, van Emmerik N, Kathmann I, Rijksen G, Jackman AL and Schornagel JH (1991) Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: Role of carrier-and receptor-mediated transport systems. Cancer Res 51:5507-5513.
386. Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ and Jansen G (1995) Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate binding protein. Cancer Res 55:3795-3802.
387. Wheeler JJ, Wong KF, Ansell SM and Bally MB (1994) Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83:1558-1564.
388. White RM (1997) Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma. AIDS 11:1412-1413.
389. Wiley JS, Jones SP, Sawyer WH and Paterson ARP (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69:479-489.
390. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ and Bankert RB (1993) Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 53:3964-3967.
391. Woodle MC and Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171-199.
392. Woodle MC, Matthay KK, Newman MS, Hidayat JE, Collins LR, Redemann C, Martin FJ and Papahadjopoulos D (1992) Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta 1105:193-200.
393. Woodle MC, Raynaud FI, Dizik M, Meyer O, Huang SK, Jaeger AJ, Brown BD, Brown BD, Judson IR and Papahadjopoulos D (1997) Oligonucleotide pharmacology and formulation: G3139 anti-bcl2 phosphorothioate in stealth liposomes and gel implants. Nucleosides Nucleotides 16:1731-1734.
394. Working PK (1998) Pre-clinical studies of lipid-complexed and liposomal drugs: AMPHOTEC®, DOXIL®, and SPI-77, in Medical Applications of Liposomes (Lasic DD and Papahadjopoulos D eds) pp 605-624, Elsevier Science BV, New York.
395. Working PK and Dayan AD (1996) Pharmacological-toxicological expert report: CAELYX™ (Stealth® liposomal doxorubicin HCI) (Foreword). Hum Exp Toxicol 15:751-785.
396. Working PK, Newman MS, Huang SK, Mayhew E, Vaage J and Lasic DD (1994) Pharmacokinetics, biodistribution, and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J Liposome Res 4:667-687.
397. Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Sahenk Z and Turner N (1998) Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomogus monkeys. Toxicol Sci 46:155-165.
398. Working PK, Newman MS, Sullivan T and Yarrington J (1999) Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating pegylated liposomes. J Pharmacol Exp Ther 289:1128-1133.
399. Wu NZ, Braun RD, Gaber MH, Lin GM, Ong ET, Shan SQ, Papahadjopoulos D and Dewhirst MW (1997) Simultaneous measurement of liposome extravasation and content release in tumors. Microcirculation (Lond) 4:83-101.
400. Yatvin MB, Weinstein JN, Dennis WH and Blumenthal R (1978) Design of liposomes for enhanced local release of drugs by hyperthermia. Science (Wash DC) 202:1290-1293.
401. Yokota T, Milenic DE, Whitlow M and Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408.
402. Young RC, Ozols RF and Myers CE (1981) The anthracycline antineoplastic drugs. N Engl J Med 305:139-153.
403. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin V and Jain R (1995) Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.
404. Yuan F, Lwunig M, Huang SK, Berk DA, Papahadjopoulos D and Jain RK (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356.
405. Zalipsky S, Hansen CB, Oaks JM and Allen TM (1996) Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes. J Pharm Sci 85:133-137.
406. Zelphati O and Szoka FC (1996) Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 13:1367-1372.
407. Zhang W, Guo L, Nadel JA and Papahadjopoulos D (1998) Inhibition of tracheal vascular extravasation by liposome-encapsulated albuterol in rats. Pharm Res 15:455-460.
408. Zhang R. Price JE, Fujimaki T, Bucana CD and Fidler IJ (1992) Differential permeability of the blood-brain barrier in experimental brain metastasis produced by human neoplasms implanted in nude mice. Am J Pathol 141:1115-1124.
409. Zuidam NJ, Gouw HKME, Barenholz Y and Crommelin DJA (1995) Physical (in) stability of liposomes on chemical hydrolysis: The role of lysophospholipids and fatty acids. Biochim Biophys Acta 1240:101-110.